Pembrolizumab Formulated with Berahyaluronidase Alfa

BIOLOGICAL2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Metastatic Non-small Cell Lung Cancer

Phase 3

A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)

Active, not recruitingNCT05722015

Merck Sharp & Dohme LLCMetastatic Non-small Cell Lung Cancer

Start: 2023-02-14End: 2028-05-22Updated: 2026-08-26

A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension

Active, not recruitingNCT06212752

Merck Sharp & Dohme LLCMetastatic Non-small Cell Lung Cancer

Start: 2023-06-13End: 2028-05-22Updated: 2026-08-26

Related Papers

Model-based dose selection and pharmacokinetic bridging of subcutaneous from intravenous pembrolizumab across indications.

2025-08-14

Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial.

2025-03-274 citations